Business Context and Reporting Period
This Form 8-K, dated July 8, 2022, reports on the consummation of the business combination between Social Capital Suvretta Holdings Corp. III ("SCS") and ProKidney LP on July 11, 2022. Following the closing, SCS changed its name to ProKidney Corp. and began trading on the Nasdaq Capital Market under the symbol "PROK". The filing also addresses a Nasdaq delisting notice regarding audit committee composition, which the company expects to be resolved due to the closing of the transaction.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or margin data for the reporting period. Key capital structure and transaction metrics include:
- Share Redemptions: 22,829,769 SCS Class A ordinary shares were presented for redemption in connection with the business combination.
- Equity Plans: Shareholders approved the ProKidney Corp. 2022 Incentive Equity Plan, reserving 26,439,000 Class A ordinary shares (subject to a 10% cap on fully-diluted shares outstanding).
- Employee Stock Purchase Plan: Shareholders approved a plan reserving 5,287,800 Class A ordinary shares (subject to a 2% cap on fully-diluted shares outstanding).
- Authorized Capital: The authorized number of Class B ordinary shares was increased from 50,000,000 to 500,000,000.
Material Changes and Voting Results
At the Extraordinary General Meeting, 25,036,611 shares (78.5% of outstanding shares) were represented. All major proposals were approved by shareholders:
- Business Combination: Approved with 23,502,858 votes for, 1,513,013 against, and 7,117 abstentions.
- Name Change: Approved to "ProKidney Corp." with 23,502,857 votes for.
- Director Elections: All eight nominated directors (including Pablo Legorreta as Chairperson) were elected unanimously with 6,250,000 votes for each and zero votes against.
- Stock Issuance: Approved to issue shares to ProKidney and PIPE investors with 22,763,337 votes for.
- Auditor Ratification: Marcum LLP was ratified as the independent auditor with 25,027,946 votes for.
Outlook, Risks, and Unusual Items
Delisting Notice: On July 8, 2022, Nasdaq notified SCS of procedures to delist its securities due to non-compliance with audit committee composition requirements (Nasdaq Listing Rule 5605(c)(2)). The company states that the closing of the business combination has rendered ProKidney Corp. compliant and expects Nasdaq to cancel the delisting actions.
Trading Status: ProKidney Corp. Class A ordinary shares were expected to begin trading under the symbol "PROK" on July 12, 2022.
Management Commentary: The filing confirms the successful closing of the transaction and the adoption of new equity incentive plans to align with the post-combination corporate structure.
Investor Verification Checklist
- Verify the final post-closing share count and the impact of the 22,829,769 redemptions on the company's cash position.
- Confirm the cancellation of the Nasdaq delisting notice and the company's current compliance status with Listing Rule 5605(c)(2).
- Review the definitive proxy statement for details on the Earnout Shares and Earnout RCUs excluded from the equity plan caps.
- Monitor the commencement of trading under the new ticker symbol "PROK" on the Nasdaq Capital Market.
- Assess the dilution impact of the 26,439,000 shares reserved for the Incentive Equity Plan and the 5,287,800 shares for the Employee Stock Purchase Plan.